New blood biomarker could enhance early detection of heart attack risk
23 March 2017
When it comes to predicting who’s at risk of suffering a heart attack or other major cardiac events, physicians have long relied on detecting high levels of C-reactive protein (CRP), an inflammatory biomarker. But new research suggests CRP may not be the only game in town.
Doctors in New Zealand—the only non-U.S. country that allows DTC advertising—call for bans
22 March 2017
Just like the United States does, New Zealand allows DTC pharma advertising. And just like in the U.S., many doctors there would like to ban the ads. Both the Royal New Zealand College of General Practitioners and the New Zealand Medical Association have come out recently with statements against DTC ads, as reported in New Zealand Doctor magazine. Both groups have called for a total ban on DTC ads, much the way the American Medical Association and American Society of Health-System Pharmacists did in the U.S.
What’s on biopharma’s auction block? EY tracks a growing appetite for pipeline divestment deals
22 March 2017
Last fall the research arm of the Financial Times went out and took the industry’s pulse on dealmaking. And they found that there’s been a big increase in appetite for divestments in the life sciences business, according to the EY M&A Outlook and Firepower Report 2017.
Google made investment in new antibiotics startup
21 March 2017
GV, the venture capital arm of Google, led an estimated $51 million investment round in Spero Therapeutics, a Cambridge, Massachusetts-based biotech developing a new class of antibiotic treatments targeting some of the toughest drug-resistant bacterial infections.
Big Data: Is It Crunch Time for Pharma?
21 March 2017
With big data and advanced analytics progressing from fad to frontier status, Pharm Exec examines the readiness of the biopharma industry to take advantage of this promise. Can new digital health tools be harnessed to help advance new treatment approaches and aid decision-making?
The UK's Catapult to Drug Discovery Collaboration
20 March 2017
Pharm Exec speaks to Chris Molloy, CEO of the Medicines Discovery Catapult, about how the organization aims to establish new approaches that draw on the combined strengths of the UK’s private, public and not-for-profit sectors to grow and sustain the country’s reputation for innovative, fast-to-patient drug discovery.
2017 NVCA Yearbook Highlights Busy Year for Venture Industry and NVCA
20 March 2017
The National Venture Capital Association (NVCA) today released the 20th edition of the annual NVCA Yearbook, documenting trends and analysis of venture capital activity in the United States from the past year and capturing historical data and information about venture’s role in fueling entrepreneurship in America. The report shows that the number of life science deals as a share of overall venture deal count increased to 12.5% in 2016.
Will Pharma Manufacturing Move Back to the US?
17 March 2017
The bio/pharmaceutical industry is still buzzing about President Trump’s meeting with pharmaceutical executives on Jan. 31, 2017 (1). While promising the industry lower taxes and less regulation, the President emphasized that those benefits will come only if the industry lowers drug prices and moves more manufacturing back to the United States.
Russian Ministry will establish new bio-targets for drug analogues developing
17 March 2017
The Ministry of Industry and Trade of Russia will make changes to the List of bio-targets for developing the analogs of innovative medicinal products that are similar and improved in terms of their pharmacotherapeutic effect.
UK life sciences sector productivity double national average
16 March 2017
The PwC report, commissioned by the Association of the British Pharmaceutical Industry (ABPI) and supported by the Association of the British Healthcare Industry (ABHI), the BioIndustry Association (BIA), and the British In Vitro Diagnostics Association (BIVDA), shows that the average productivity of UK life sciences employees, expressed as gross value added (GVA), is £104,000, compared to the UK average of £49,000.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024